Advanced Search
DSpace@MIT

The accelerated approval process in oncology : an examination of the conversion rate of approved therapies to full approval

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Ernst R. Berndt and Frank L. Douglas. en_US
dc.contributor.author Kim, Jean Jinsun en_US
dc.contributor.other Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.date.accessioned 2007-01-10T16:37:36Z
dc.date.available 2007-01-10T16:37:36Z
dc.date.copyright 2006 en_US
dc.date.issued 2006 en_US
dc.identifier.uri http://hdl.handle.net/1721.1/35553
dc.description Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006. en_US
dc.description Includes bibliographical references. en_US
dc.description.abstract In 1992, Accelerated Approval, or Subpart H approval, was added to the NDA regulations so promising products that provide a meaningful therapeutic benefit for serious or life-threatening diseases could be introduced to the market sooner, particularly for diseases or conditions where there was a great unmet medical need. Accelerated Approval is based on either a surrogate endpoint that is reasonably likely to predict clinical benefit or a clinical endpoint other than survival or irreversible morbidity. After approval, the sponsor is required to perform post-marketing studies to demonstrate clinical benefit. Since the FDA expanded the use of the Accelerated Approval regulatory path to include oncology drugs in 1995, thirty drugs (both small molecule as well as biologics) have been granted accelerated approval in oncology. However, from various reports in the literature and the FDA site, it appears that only a small fraction of these approvals (four to six) have been converted into regular approvals, based on the demonstration of clinical benefit in the post-marketing studies that support the benefit seen in the pivotal studies. en_US
dc.description.abstract (cont.) In my research, I examined the basis of approval for six drugs that were converted to full approval and compared this group to the seven drugs that received accelerated approval before 2000 but as yet have not converted to full approval. The six drugs that were converted to full approval, with the exception of dexrazoxane, completed their post-marketing requirements in 2.3 years after initial approval. The sponsors, who were all well-capitalized pharmaceutical companies, also pursued additional indications for these drugs. In the group of drugs that were designated as "not converted" by several sources, two of the drugs have been granted full approval within the past year. And in March 2006, the FDA withdrew its accelerated approval for one drug based on the results of a negative clinical trial. Six years after having received accelerated approval, two drugs in this group are still undergoing clinical trials. Due to the lack of information about the ongoing trials, it is difficult to assess the underlying reasons for the delay in attaining full approval. But the sponsors of these two drugs are small biotechnology companies, while all of the sponsors of the drugs that have been converted to full approval are major pharmaceutical companies. en_US
dc.description.abstract (cont.) A majority of the drugs that converted to full approval were granted a broader label based on the post-marketing studies, which demonstrated clinical benefit in a wider patient population than originally tested. While the accelerated approval process holds many advantages in that companies can introduce their drug to the market sooner, the requirements for accelerated approval often result in the drugs having to meet 'a higher standard' in that they have to demonstrate "meaningful clinical benefit" over existing agents, which may in fact be a requirement for superiority, as was seen in the case of one agent, Doxil. The post-marketing studies can be expensive and difficult to complete, but companies with ample resources and sufficient incentives, such as additional potential indications, seem able to clear this hurdle easily. en_US
dc.description.statementofresponsibility by Jean Jinsun Kim. en_US
dc.format.extent 82 leaves en_US
dc.format.extent 6601439 bytes
dc.format.extent 6603691 bytes
dc.format.mimetype application/pdf
dc.format.mimetype application/pdf
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri http://dspace.mit.edu/handle/1721.1/7582
dc.subject Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.title The accelerated approval process in oncology : an examination of the conversion rate of approved therapies to full approval en_US
dc.type Thesis en_US
dc.description.degree S.M. en_US
dc.contributor.department Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.identifier.oclc 73805013 en_US


Files in this item

Name Size Format Description
73805013.pdf 6.295Mb PDF Preview, non-printable (open to all)
73805013-MIT.pdf 6.297Mb PDF Full printable version (MIT only)

This item appears in the following Collection(s)

Show simple item record

MIT-Mirage